...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: 50/50 at best on Zen being sold this year IMO..

maybe a new partner or two or one & done this year??

No panic to sell or go public??? - heard he's raising or trying to raise more @$2US as a type?? Anyone else been approached yet again to partake at the same price as last year?? How does this even begin to add up/make any sense???

can you imagine being the folks who dropped off $100k to 1million over a year ago based @$2US/unit & being told this thing will be gone by June 2019 & now your learning Dm is still trying to raise more money @ the same $2US over a FULL YEAR LATER???

Your money is frozen/dead with no way out....other than maybe a grey market slaughter price...???

Its sad IMO but with little to no information or guidance coming from the company we are all left speculate.

Share
New Message
Please login to post a reply